This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Johnson & Johnson

Drug Names(s): JNJ-2847922, JNJ-922, MIN-202

Description: JNJ-42847922 is a selective orexin 2 receptor antagonist.

Deal Structure: JNJ-42847922 was originally developed by Johnson & Johnson.

JNJ and Minerva Neuroscience
In February 2014, Janssen granted Minerva Neurocience an exclusive license (even as to Janssen), with the right to sublicense, in the European Union, Switzerland, Liechtenstein, Iceland and Norway, referred to as the Minerva Territory, under certain Janssen patent and patent applications to sell products containing any orexin 2 compound, controlled by Janssen and claimed in a Janssen patent right, as an active ingredient, or MIN-202, for any use in humans. In addition, upon regulatory approval in the Minerva Territory (and earlier if certain default events occur), Minerva will have rights to manufacture or have a third party manufacture MIN-202. Minerva has granted to Janssen an exclusive license, with the right to sublicense, under all patent rights and know-how controlled by Minerva related to MIN-202 to sell MIN-202 outside the Minerva Territory. The Janssen license will...See full deal structure in Biomedtracker

Partners: Minerva Neurosciences, Inc.

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug